RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway.

Item

http://www.wikidata.org/entity/Q38924621

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway.

@en

type

Item

label

RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway.

@en

prefLabel

RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway.

@en

P1476

RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway.

@en

P2093

Baishi Wang

http://www.w3.org/2001/XMLSchema#string

Baoqing Jia

http://www.w3.org/2001/XMLSchema#string

Bing Li

http://www.w3.org/2001/XMLSchema#string

Hongyi Liu

http://www.w3.org/2001/XMLSchema#string

Jiajin Zhang

http://www.w3.org/2001/XMLSchema#string

Peng Li

http://www.w3.org/2001/XMLSchema#string

Peng Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP

Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.

Role of NF-κB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy.

The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit

Raf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression.

RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy

Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension.

Identification of novel metastasis suppressor signaling pathways for breast cancer

Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor.

Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments.

P2888

s13277-014-2496-6

P304

1445-1453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-014-2496-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027656351

http://www.w3.org/2001/XMLSchema#string

P698

25547433

http://www.w3.org/2001/XMLSchema#string

P921

NF-κB